Houman is a partner at SV Health Investors. He co-founded the services company Cardiac Report in 2003, as well as Heart Metabolics in 2008, which successfully repositioned perhexiline as a treatment for hypertrophic cardiomyopathy and heart failure. Prior to joining SV Health Investors Houman was Vice President and head of the Clinical Science Group at UCB Pharma.
Following the completion of his cardiology training, Houman was appointed as an Honorary Consultant Cardiologist in 2011 at the John Radcliffe Hospital in Oxford. Houman is also the co-founder and Chairman of Weatherden, a boutique clinical development company. Houman holds a postgraduate degree from the University of Oxford.
Luke holds the Chair of Biochemistry at Trinity College Dublin where he leads the Inflammation Research Group. After receiving his PhD in Pharmacology from the University of London, he carried out postdoctoral research at the Strangeways Research Laboratory in Cambridge funded by the Medical Research Council. His research is focussed on the molecular basis of inflammation, with a particular emphasis on innate immunity, toll-like receptors, inflammasomes and metabolic reprogramming in macrophage activation.
In 2016 he was named by Clarivates/Thompson Reuters as one of the world’s most influential scientists, being in the top 1% in Immunology. He has won numerous awards for his research including the European Federation of Immunology Societies medal, the International Cytokine and Interferon Society Milstein Award, The Royal Dublin Society Boyle Medal for Scientific Excellence, and The Royal Irish Academy Gold Medal for Life sciences. He was elected a Fellow of the Royal Society in 2016.
Jonathan Powell is Professor of Oncology and Associate Director at the Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins University School of Medicine and Oncology. Jonathan’s research interests are in cancer immunotherapy, mechanisms of T cell activation and tolerance and bone marrow transplantation.
Jonathan received his PhD in Immunology from Emory University School of Medicine and completed his residency at Johns Hopkins University School of Medicine. Jonathan is also one of the scientific founders of Dracen Pharmaceuticals.
Jeff is Associate Director of the Vanderbilt Institute of Infection, Immunology, and Inflammation and co-leader of the Molecular Pathology and Immunology PhD training program. His prior positions include Professor of Pathology, Microbiology, and Immunology to direct the Vanderbilt Center for Immunobiology and co-lead the Vanderbilt Ingram Cancer Center Host Tumor Interactions Program. Jeff studies mechanisms that influence lymphocyte fate and differentiation in inflammatory diseases and cancer with a particular focus on metabolic mechanisms of cell regulation.
Following undergraduate studies in Biology at the University of Northern Iowa, Jeff earned a PhD in Immunology on B cell tolerance and death mechanisms at Stanford University. He completed postdoctoral studies at the University of Chicago and the University of Pennsylvania showing that the metabolism of lymphocytes was dynamically regulated to control cell function and survival in inflammatory diseases and cancer.
Michael is an Associate Professor in the Department of Dermatology at the University of California, San Francisco. Michael's central focus is to understand how immune responses are regulated in tissues and how this knowledge can be exploited for therapeutic benefit. Michael's research focuses on understanding the fundamental mechanisms of how immune responses are regulated in peripheral tissues, and how this knowledge can be exploited to treat human disease. He recently helped to generate and validate a novel therapeutic molecule that selectively activates human Tregs which is currently being tested in clinical trials in patients with autoimmune diseases.
Michael received his PhD in Immunology from Medical College of Wisconsin, Milwaukee.
Paul-Peter is the former Chief Immunology Officer, Global Development Leader and Senior Vice President R&D Pipeline at GSK, and Professor of Medicine, Amsterdam University Medical Centre. During his time at GSK, Paul-Peter created the Immunology Network, an innovative collaboration between GSK and several international universities which offers access to GSK's research and development facilities and supported the creation of Sitryx. Paul-Peter is an immunologist, academic and entrepreneur, specialising in the field of rheumatology, combining academic research and clinical practice to inform and develop commercial applications in the field of immunotherapy. Paul-Peter is on the Board of Directors for several pharmaceutical biotech companies, a Fellow of the Academy of Medical Sciences, and President and CEO of Kintai Therapeutics.
Paul-Peter received his Medical Degree cum laude from the Free University in Amsterdam and was trained as an internist, rheumatologist and immunologist at Leiden University Medical Center, where he also received his PhD.
Sitryx was founded by six world leading researchers in the field of immunology and immuno-regulation with the aim of building a biopharmaceutical company focused on the development of disease modifying therapeutics for treating cancer and inflammatory disorders.